Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to improve life quality in AML patients too sick for standard chemo

NCT ID NCT06181734

Completed Disease control Sponsor: iOMEDICO AG Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how adults with a specific type of acute myeloid leukemia (AML) who cannot receive standard chemotherapy feel and function while taking a combination of ivosidenib and azacitidine. The main goal was to measure quality of life using questionnaires, along with checking how well the treatment works and its safety. Only 8 patients were enrolled in Germany, making this a very small observational study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ivosidenib and azacitidine
What this could lead to
If successful, this could show that the combination improves quality of life and controls AML in patients who cannot tolerate standard chemotherapy.
What could go wrong
This is a small, completed observational study with only 8 participants, so results may not apply broadly. It does not test a new treatment but observes real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA (AML)

Contacts and locations

Locations

  • Praxis für interdisziplinäre Onkologie & Hämatologie

    Freiburg im Breisgau, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.